Sigyn Therapeutics (SIGY) Cash & Current Investments (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Cash & Current Investments of $85571.0 for Q3 2025, up 18542.92% sequentially from $459.0 in Q2 2025, and down 48.07% YoY from $164788.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Cash & Current Investments (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Cash & Current Investments for 10 years, with the latest figure at $85571.0 in Q3 2025.
- Quarterly Cash & Current Investments fell 48.07% year-over-year to $85571.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $85571.0 (down 48.07% YoY) and the FY2024 annual result came in at $12144.0, up 3.88% from the prior year.
- Cash & Current Investments improved to $85571.0 in Q3 2025 per SIGY's latest filing, from $459.0 in the prior quarter.
- Over five years, Cash & Current Investments peaked at $1.1 million in Q2 2021 and troughed at $459.0 in Q2 2025.
- A 5-year average of $148461.3 and a median of $32838.0 in 2024 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2021 and 2022: Cash & Current Investments jumped 116383.19% in 2021, then plunged 99.31% in 2022.
- Over 5 years, Cash & Current Investments stood at $340956.0 in 2021, then plunged by 97.55% to $8356.0 in 2022, then surged by 39.9% to $11690.0 in 2023, then advanced by 3.88% to $12144.0 in 2024, then soared by 604.64% to $85571.0 in 2025.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $85571.0, $459.0, and $12895.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 85,571.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 85,571.00 |
| Jun 30, 2025 | 459.00 |
| Mar 31, 2025 | 12,895.00 |
| Dec 31, 2024 | 12,144.00 |
| Sep 30, 2024 | 164,788.00 |
| Jun 30, 2024 | 53,644.00 |
| Mar 31, 2024 | 32,838.00 |
| Dec 31, 2023 | 11,690.00 |
| Sep 30, 2023 | 64,584.00 |
| Jun 30, 2023 | 23,633.00 |
| Mar 31, 2023 | 322,327.00 |
| Dec 31, 2022 | 8,356.00 |
| Sep 30, 2022 | 28,123.00 |
| Jun 30, 2022 | 7,291.00 |
| Mar 31, 2022 | 81,385.00 |
| Dec 31, 2021 | 340,956.00 |
| Sep 30, 2021 | 502,976.00 |
| Jun 30, 2021 | 1.06 Mn |
| Mar 31, 2021 | 7,107.00 |
| Dec 31, 2020 | 84,402.00 |